Transforming growth factor-b type 1 (TGF-b) has been implicated as both a tumor suppressor and a tumor promoter in many solid epithelial cancers. We have previously demonstrated that the cyclin dependent kinase (CDK) inhibitor p21 acts as a molecular switch in determining a growth inhibitory versus growth proliferative response to TGF-b in the spontaneously immortalized human mammary epithelial cell line MCF-10A. We now demonstrate that this proliferative effect of TGF-b is mediated through the proinflammatory cytokine, interleukin-1a (IL-1a). Using gene expression array analysis, we identified IL-1a as a cytokine specifically upregulated only in cells lacking p21 and only upon TGF-b stimulation. Cell proliferation assays verified that recombinant IL-1a was capable of inducing a growth proliferative response in p21 null MCF-10A cells, while neutralizing antibodies against IL-1a prevented the growth proliferative effects of TGF-b. Mechanistically, both the CDK and proliferating cell nuclear antigen (PCNA) inhibitory functions of p21 were responsible for preventing TGF-b induced cell proliferation, but only PCNA inhibition by p21 regulated IL-1a gene expression. These studies demonstrate a novel role for IL-1a in mediating a proliferative response to TGF-b signaling, and suggest that therapies directed against IL-1a could abate the growth proliferative effects of TGF-b without compromising its tumor suppressive function.
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The transforming growth factor-beta (TGF-b) signaling pathway has continued to challenge cancer researchers because of its dual role as a tumor suppressor and a tumor promoter (reviewed in Siegel and Massague (2003) , Bachman and Park (2005) ). Although studies have demonstrated that TGF-b normally acts to suppress the growth of epithelial cells, it has now been firmly established that certain cancers have evolved mechanisms to evade the growth inhibitory effects of this cytokine. For example, it has been shown by several groups that mutations in the TGF-b type II receptor and the downstream transcription factor Smad4 abrogate TGF-b signaling in gastrointestinal malignancies, rendering these cancers unresponsive to growth inhibition by TGF-b (Markowitz et al., 1995; Hahn et al., 1996) . The mechanisms used by other non-gastrointestinal epithelial cell malignancies, however, have been less well characterized and only recently have studies yielded molecular explanations as to how these cancers evade the growth inhibitory properties of this ubiquitous cytokine (Cordenonsi et al., 2003; Seoane et al., 2004) . Equally perplexing is that many human cancers are capable of using TGF-b as a growth promoting factor, including enhancement of cell proliferation, invasiveness and the ability of cancer cells to metastasize (Yin et al., 1999; Lei et al., 2002) . As a result of its dual function in mediating carcinogenesis, the development of therapeutics that selectively target the growth promoting arm of this pathway has remained a major challenge. Although much work has been focused on dissecting the molecular mechanisms involved with the growth inhibitory pathways of TGF-b signaling, there is still a paucity of studies examining the mechanisms implicated with TGF-b induced cell proliferation and tumor progression. In part, this is due to the lack of reagents available to examine the specific genetic changes involved with TGF-b mediated growth stimulation versus growth inhibition, as there is often no appropriate control for correlating gene expression changes with one or the other growth phenotype.
We recently described a model system whereby somatic cell gene deletion of the CDK inhibitor p21 in the MCF-10A and HCT 116 cell lines led to a dramatic alteration in their responses to TGF-b (Bachman et al., 2004) . The MCF-10A cell line is a spontaneously immortalized non-tumorigenic human mammary epithelial cell line that is normally growth inhibited by TGF-b (Iavarone and Massague, 1997) . Targeted deletion of the p21 gene in this cell line conferred resistance to TGF-binduced growth inhibition, and surprisingly p21 null cells could subsequently use TGF-b as a mitogenic stimulus, as measured by growth assays, hyperphosphorylation of pRB and cell cycle FACS analyses. p21 null cells also displayed an epithelial to mesenchymal transition (EMT) upon prolonged exposure to this cytokine as demonstrated by decreased E-cadherin expression and an increase in expression of the cytoskeletal gene vimentin, often used as a marker for TGF-binduced EMT (Islam et al., 2000; Derynck et al., 2001; Grille et al., 2003) . Our study also demonstrated that in a panel of primary human breast cancers, loss of p21 correlated with increased vimentin gene expression. Our MCF-10A p21 null system provides a unique opportunity to analyse and identify downstream genetic effectors that are specific for a growth stimulatory or growth inhibitory phenotype versus downstream gene expression changes that are common to both TGF-b pathways.
In this study, we wished to determine the downstream effectors that were specific for the proliferative effects of this cytokine. The fact that p21 null cells display an opposite phenotype compared to their parental MCF-10A counterparts, but differ only by the presence or absence of a single gene, allows us to directly compare the genetic changes associated with generalized TGF-b signaling versus gene expression changes unique to a growth stimulatory (or growth inhibitory) phenotype. To begin these analyses, we carried out gene expression studies using Agilent Human oligo microarrays on cells cultured in parallel with and without TGF-b for 8 days. We categorized a list of genes based on their known functions and verified their gene expression changes using quantitative real time reverse transcriptase-polymerse chain reaction (RT-PCR) ( Table 1 ). As demonstrated in Table 1 , there were many genes whose expression changed with the addition of TGF-b regardless of the growth phenotype, though the magnitude of the response varied between cell lines. For the purposes of our study, we were interested in identifying genes whose expression was uniquely upregulated in p21À/À cells upon TGF-b administration. Somewhat surprisingly, only three genes present on our array were verified to be exclusively upregulated in the growth proliferative phenotype p21À/À cell lines (Table 1) . Two of these genes were the metallothioneins, MT1E and MT1X. This class of genes has previously been implicated with human cancers (Theocharis et al., 2004) . The third gene was the cytokine IL-1a. Of these three genes, IL-1a was initially chosen for further analysis as we were intrigued by the possibility that a soluble factor might lend itself more amenable for future targeted therapy. As shown in Table 1 , we also verified seven genes upregulated exclusively in parental MCF-10A cells upon TGF-b exposure. As these genes potentially represent unique effectors of the TGF-b growth inhibitory pathway, the characterization of these genes, as well as MT1E and MT1X, is ongoing and will be described separately elsewhere.
Previous microarray expression studies examining TGF-b response genes in MCF-10A cells demonstrated that the transcription factors ID1 and C-MYC were downregulated more than twofold (Chen et al., 2001) . Although these two genes did not meet our statistical cut off and criteria for further examination, our primary data are in agreement with these studies as ID1 and C-MYC gene expression were decreased in MCF-10A cells upon TGF-b exposure. However, p21 null cells displayed an equivalent degree of ID1 gene downregulation, whereas C-MYC gene expression was slightly increased in p21 null cells after TGF-b stimulation (data not shown).
As shown in Figure 1a , our initial quantitative real time RT-PCR analysis was confirmed using independent samples of mRNA from parental MCF-10A and p21À/À cells with and without TGF-b treatment cultured for 4 days. These data demonstrated that IL-1a was increased three to sixfold only in p21 null cells and only upon TGF-b exposure. Time point analyses demonstrated that IL-1a mRNA upregulation was rapid, occurring within 30 min of TGF-b exposure, peaked at 1 h and was completely absent within 24 h (data not shown). The kinetics of this gene regulation are consistent with the known half lives of TGF-b and IL-1a mRNA and the fact that TGF-b containing medium needs to be replenished daily to obtain maximum mitogenic stimulation (Turner et al., 1989; Wakefield et al., 1990) . To determine if this effect was unique to MCF-10A cells or more broadly applicable, we examined two additional human cell lines previously described to have a growth stimulatory response to TGF-b. One cell line was the HCT 116 p21À/À colon cancer cell line, which we characterized as having a proliferative response to TGF-b upon reconstitution of the Type II TGF-b receptor (Bachman et al., 2004) . The other cell line examined was the human osteosarcoma cell line KHOS-240s. This cell line, along with other osteosarcoma cell lines, has also been described as having a mitogenic response to exogenous TGF-b (Kloen et al., 1994a, b) . As seen in Figure 1a , p21À/À HCT 116 cells and the KHOS-240s cell line both increased IL-1a gene expression upon TGF-b exposure as measured by real time quantitative RT-PCR. This effect was not seen in parental HCT 116 cells. Although by definition, p21À/À HCT 116 cells do not contain any wild-type p21 protein, we wanted to examine if the p21 status of KHOS-240s cells correlated with its ability to upregulate IL-1a message with TGF-b stimulation. As seen in Figure 1b , Western blot analysis of these cell lines demonstrated that the absence of p21 protein correlated with the ability of cell lines to upregulate IL-1a gene expression upon TGF-b exposure. Having confirmed the link between TGF-b, IL-1a gene expression and the absence of p21 in additional cell lines, we chose to focus our experiments using the MCF-10A system, as the ability to completely arrest these cells in G1 provides a unique advantage in assessing growth responses compared to cancerous cell lines (see below).
In order to quantify actual levels of IL-1a production, Western blot analysis was then performed to determine if cellular IL-1a protein was increased upon TGF-b exposure. Only small amounts of protein were visible by this analysis, making quantification by this method unreliable (data not shown). We reasoned that perhaps the minute amount of IL-1a protein being produced by p21 null cells was secreted and metabolized, thus making detection by Western blot analysis problematic. We next performed an ELISA to determine if IL-1a protein was being secreted into the culture supernatants of p21À/À cells exposed to TGF-b after 4 days in culture. As demonstrated in Figure 1c , the addition of TGF-b dramatically increased the amount of IL-1a protein secreted into the culture supernatants of p21À/À cell lines. These data verify that IL-1a gene expression was specifically upregulated in p21 null cells upon TGF-b exposure and therefore correlated with the proliferative cellular response to this cytokine.
Cell proliferation experiments were performed using parental MCF-10A cells and their p21À/À counterparts to determine whether exogenous recombinant human IL-1a (rhIL-1a) could serve as a mitogenic factor to stimulate cell growth and proliferation. For proliferation assays, epidermal growth factor (EGF) is removed from the medium which normally induces a G1 arrest in MCF-10A cells as previously described (Chou et al., 1999) . Moreover, cells remain completely viable as long as the medium is replenished daily. This serves a dual purpose: First, any increases in cell number reflect only cell proliferation and not increased cell survival, since the arrested cells have no ongoing cell growth or cell death. Second, removal of EGF and subsequent G1 arrest greatly enhances our ability to observe the Gene expression was verified by quantitative real time RT-PCR using primers listed in Supplementary Information. Shown in bold are genes specifically upregulated during TGF-b (2 ng/ml) (R&D systems, Minneapolis, MN, USA) induced cell proliferation after 4 days in culture. Media was changed daily and cells were harvested 1 h after the media was changed on day 4. For the original microarray experiments, cells were cultured with and without TGF-b for 8 days, with daily media changes. On day 8, cells were harvested 1 h after the media was changed for RNA using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) and the RNeasy system (Qiagen, Valencia, CA, USA). RNA was labeled and hybridized to the Agilent Human 1A(V2) 22K oligo microarray chip according to the manufacturer's protocols (Agilent Technologies, Palo Alto, CA, USA). Gene selection among classes was performed, based on linear discriminate analysis, as previously described (Bittner et al., 2000) . Gene expression changes for p21À/À cells are averaged from two independent clones.
IL-1a mediates TGF-b cell proliferation B Karakas et al mitogenic effects of other cytokines, providing a very sensitive cell proliferation assay. As depicted in Figure 2a , addition of rhIL-1a dramatically affected the proliferation of p21 null cells, however this cytokine did not completely reconstitute the cellular proliferative effects of TGF-b in p21À/À cells. This finding suggests that other mediators of TGF-b-induced cell proliferation likely exist. Interestingly, rhIL-1a also had a slight proliferative effect on parental MCF-10A cells. This seemingly conflicting result further supports the significance of IL-1a in mediating a specific TGF-b growth proliferative effect, as endogenous IL-1a is only upregulated upon TGF-b exposure in the absence of p21 and not in parental MCF-10A cells. As a control, the interleukin, IL-15, whose gene expression increased equally in response to TGF-b in parental and p21 null cell lines (Table 1) , was tested in our proliferation assays, and did not demonstrate any ability to stimulate cell proliferation (Figure 2b) . In order to provide further evidence that endogenous IL-1a was acting as a downstream effector of TGF-b mediated cell growth in p21 null cells, we next performed proliferation assays with neutralizing IL-1a antibodies (IL-1a Ab) to determine if we could block the mitogenic effects of TGF-b in p21À/À cells. The results shown in Figure 2c demonstrate that co-incubation of IL-1a Ab with TGF-b, abrogates the cellular proliferation normally induced by TGF-b in the p21À/À cell lines. As a control, bovine serum albumin was added to TGF-b containing cultures at the same concentration used for IL-1a Ab. However, this did not affect TGF-b's ability to stimulate cell proliferation in p21À/À cells. As expected, the negative controls BSA and IL-1a Ab alone did not affect cell proliferation in p21 null cells. Taken (Bachman et al., 2004) . Cells were cultured with and without TGF-b for 4 days with daily media changes. On day 4, cells were harvested for RNA 1 h after the media was changed. Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) and the RNeasy system (Qiagen, Valencia, CA, USA). cDNA was generated using First Strand cDNA Synthesis Kit corresponding to the human IL-1a promoter was polymerase chain reaction (PCR) amplified using human genomic DNA as template with the primer sequences 5 0 -TTCATTTGCTAAGAGTCTGGTG-3 0 and 5 0 -AACGCCAATGAAATGACTCC-3 0 forward and reverse, respectively. This was cloned into a modified pEGFP-N1 vector (Clontech, Palo Alto, CA, USA), such that the CMV promoter driving expression of EGFP was completely replaced with the IL-1a promoter, upstream of the initiating ATG codon of the EGFP gene. The entire region was sequenced to verify the absence of PCR mutations. MCF-10A cells and their p21À/À derivatives were transiently transfected with this human IL-1a promoter GFP reporter construct using Fugene 6 (Roche, Indianapolis, IN, USA) and then exposed to TGF-b or vehicle control. Cells were visualized sixteen hours after transfection/TGF-b stimulation using phase contrast and filtered UV light microscopy. As a control, cells were also transiently transfected with pEGFP containing no promoter (control) (shown only for MCF-10A). To control for transfection efficiencies, cells were transfected in parallel and then harvested 24 h after transfection for DNA using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA). DNA was subjected to quantitative real time PCR using GAPDH primers specific for genomic DNA 5 0 -ACATCATCCCTGCCTCTAC-3 0 (forward), 5 0 -TCAAAGGTGGAGGAGTGG-3 0 (reverse) and primers specific for the GFP reporter plasmid 5 0 -ATCTAGCCCCTTGACTTCG-3 0 (forward) and 5 0 -AACTTCAGGGTCAGCTTGCC-3 0 (reverse) to quantify the amount of transfected plasmid relative to cell number as described in Figure 4 
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B Karakas et al together, these results strongly suggest that IL-1a is capable of acting as a 'second messenger' in mediating the growth proliferative effects of TGF-b. In order to gain mechanistic insight into how the absence of p21 leads to the upregulation of IL-1a gene expression upon TGF-b exposure, we developed several in vitro assays. Using a green fluorescence protein (GFP) promoter reporter assay, we initially examined the effect of p21 on the IL-1a promoter in the presence or absence of TGF-b to determine whether loss of p21 allows TGFb to increase IL-1a promoter activity. As seen in Figure 3a , increased GFP driven by the IL-1a promoter was only seen in p21 null cells and only upon TGF-b exposure. As there is a minute amount of low-level basal GFP even in the unstimulated (no TGF-b) transfected cell lines, and the fact that GFP has a relatively long half life, it was feasible that this increase in GFP was due to increased message stability upon TGF-b exposure rather than an increase in gene transcription. To address this question, p21 null cells were treated with the transcriptional inhibitor actinomycin D prior to TGF-b stimulation, followed by assessment of IL-1a gene expression using quantitative real time RT-PCR. As seen in Figure 3b , pre-treatment with actinomycin D completely ablated the ability of TGF-b to increase IL-1a message compared to mock treated controls. Gene expression of Figure 4 The PCNA inhibitory function of p21 regulates IL-1a gene expression in response to transforming growth factor-beta (TGFb). (a) Schematic diagram of p21 wild-type (p21wt) and p21 mutant (p21CDKÀ, p21PCNAÀ) cDNAs/protein sequences used for transient transfection assays. Cyclin, CDK and PCNA represent the p21 binding sites for cyclins, cyclin dependent kinases and proliferating cell nuclear antigen, respectively. (b) The CDK and PCNA inhibitory functions of p21 are partially responsible for suppressing TGF-b mediated growth. Wild-type and mutant p21CDK (À), p21PCNA (À) plasmids were polymearse chain reaction (PCR) amplified and subcloned into pIRESpuro2 (Clontech, Palo Alto, CA, USA) at the NotI restriction enzyme site, and verified by automated sequencing. These plasmids, along with empty vector control, were transiently transfected into MCF-10A p21À/À cells as described (Bachman et al., 2004) and cells were then subjected to growth assays with and without TGF-b as described in Figure 2 . Cells were harvested after 6 days in culture and quantified. Results are expressed as relative differences in cell growth with and without TGFb stimulation ( þ TGF-b/ÀTGF-b). Error bars represent the standard error of the mean from triplicate samples and results are representative of three independent experiments. (c) The PCNA inhibitory activity of p21 is responsible for regulating IL-1a gene expression. The p21 constructs described above and empty vector control were transiently transfected into p21À/À cells using Fugene 6. Following overnight incubation, cells were seeded in EGF free medium the next day. On the following day, cells were switched to EGF-free media containing 2 ng/ml of TGF-b or vehicle control. After 1 h in culture, cells were harvested for RNA and used for quantitative real time reverse transcript-polymerase chain reaction (RT-PCR) analysis as described above. Results are expressed as fold increase gene expression with and without TGF-b stimulation ( þ TGF-b/ÀTGF-b). Error bars represent the s.e. of the mean from triplicate samples and results are representative of three independent experiments. (d) Transfection efficiencies of p21 plasmids are equivalent. Equivalent amounts (1 mg) of p21 plasmids and empty vector control were transfected into p21 null cells seeded at equal density in parallel with experiments shown in (b) and (c). After 24 h post transfection, cells were harvested for DNA using the QIAamp DNA Blood Mini Kit. DNA was then subjected to quantitative real time PCR to precisely quantify the amount of transfected plasmid normalized to genomic GAPDH to control for cell number. Primers used to quantify plasmid DNA were 5 0 -TTCGTTCATCCA-TAGTTGCC-3 0 (forward) and 5 0 -CATGTAACTCGCCTTGATCG-3 0 (reverse). GAPDH primers used are listed in above in Figure 3(a) .
IL-1a mediates TGF-b cell proliferation B Karakas et al GAPDH remained similar between actinomycin D treated and untreated cell lines serving as an internal control for non-specific toxic effects (data not shown). These results demonstrate that the increase in IL-1a seen in p21 null cells after TGF-b stimulation is indeed the result of increased gene transcription.
To determine which regulatory region of p21 was responsible for mediating the repressive effect on IL-1a gene expression, functional/mutational studies were carried out. p21 has been demonstrated to have a number of different functions, including its ability to bind and inhibit CDKs and the auxiliary DNA polymerase d protein, PCNA (Luo et al., 1995) . We obtained two previously characterized p21 mutant cDNA constructs as a generous gift from Dr Bernard Ducommun (Institut de Pharmacologie et de Biologie Structurale du CNRS Universite Paul Sabatier, France); one that is devoid of CDK inhibitory activity due to the presence of three missense mutations in the CDK binding domain, and another that has been mutated such that it has no capacity to bind and inhibit PCNA (Figure 4a ). Importantly, these two constructs have been shown to be specifically devoid of binding activity in their respective mutated domains, while retaining other functional properties of p21 (Cayrol et al., 1998) . These mutant p21 constructs along with wild type and negative controls, were transiently transfected into our p21À/À cell lines. As our p21 null cells have no detectable p21 mRNA or protein (Bachman et al., 2004) , these cells constitute an excellent model for performing these studies as we do not have the concern of endogenous p21 obscuring our results.
As seen in Figure 4b , transient transfection of wildtype p21 greatly reduced the ability of TGF-b to stimulate cell proliferation in p21À/À cells, while empty vector control plasmid had no effect on the mitogenic properties of TGF-b as expected. As depicted in Figure 4b , both mutant p21 constructs partially inhibited the growth proliferative effects of TGF-b, compared to the p21 wild-type and empty vector controls. These results suggest that both functions of p21 are separately involved in normally preventing the cell proliferation induced by TGF-b.
Quantitative real time RT-PCR analysis of IL-1a mRNA demonstrated that wild-type p21 cDNA, but not empty vector control plasmid, could decrease IL-1a gene expression following TGF-b exposure (Figure 4c ). These data validate our assay conditions, and also serve to confirm that p21 is responsible for regulating IL-1a gene expression in the presence of TGF-b. Transfection of the p21CDK-mutant cDNA decreased IL-1a gene expression in response to TGF-b to the same degree as wildtype p21 cDNA (Figure 4c ), signifying that this functional domain of p21 is not involved with repressing IL-1a gene expression upon TGF-b exposure. However, transfection of the p21PCNA-mutant had only a minimal repressive effect on IL-1a gene expression after TGF-b exposure. To ensure that the absence of decreased IL-1a message using the p21 PCNA-mutant was not due to differences in transfection efficiencies, we developed a sensitive and specific assay using template DNA harvested from cells 24 h post transfection and then subjecting this DNA to real time PCR analysis. As seen in Figure 4d , all p21 plasmids transfected equally well in p21 null cells. As the empty vector control is roughly 600 base pairs less than its p21 plasmid containing derivatives, it would be expected that on a per microgram basis this plasmid should have additional copy numbers relative to its p21 containing counterparts. This was observed in our experiments and validates the sensitivity of this assay. Together, these findings demonstrate that the capacity of p21 to bind and inhibit PCNA is directly involved with its ability to repress IL-1a gene expression upon TGF-b stimulation.
In conclusion, we have shown using a powerful genetic system that IL-1a can function as a key mediator of the growth proliferative response induced by TGF-b. As we have previously demonstrated that loss of p21 expression occurs in up to 30% of primary human breast cancers, our study opens the possibility of therapies directed against specific regulators of TGF-b induced growth. Of significant importance is the discovery of extracellular factors involved with proliferative responses as they represent attractive targets for the design and delivery of novel therapeutics. IL-1a therefore, may constitute an effective and rational target to treat pre-invasive and invasive human breast malignancies.
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